Ignite Creation Date:
2025-12-24 @ 4:38 PM
Ignite Modification Date:
2025-12-29 @ 7:22 PM
Study NCT ID:
NCT04622566
Status:
UNKNOWN
Last Update Posted:
2020-11-13
First Post:
2020-10-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
Sponsor:
Peking University Cancer Hospital & Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-12-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2021-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2020-10-28
First Submit QC Date:
None
Study First Post Date:
2020-11-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-11-10
Last Update Post Date:
2020-11-13
Last Update Post Date Type:
ACTUAL